Compare Organon & Co. Common Stock (OGN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs TransMedics Group Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while TransMedics Group Inc trades at $75.46 (market cap $2.74B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and TransMedics Group Inc for 24 Days on average.
| OGN | TMDX | |
|---|---|---|
Market Cap | $3.62B | $2.74B |
Volume | 2,892,999 | 1,025,926 |
Sector | Health | Health |
52-Week High | $13.81 | $150.42 |
52-Week Low | $5.70 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $11.04B | $3.14B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TMDX trades at $79.14, up 1.23% on the day, but faces a bearish technical outlook with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Recent news highlights insider buying and a new CFO appointment, alongside multiple legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but near-term risks include earnings volatility, legal scrutiny, and a declining net cash flow trend. Investors should weigh solid fundamentals against execution and sentiment risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
